Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free NCYT Stock Alerts

Novacyt (NCYT) Competitors

Novacyt logo
GBX 41.50 +1.40 (+3.49%)
As of 11:58 AM Eastern
Compare

NCYT vs. EKF, CREO, IUG, IHC, and RUA

Should you buy Novacyt stock or one of its competitors? MarketBeat compares Novacyt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novacyt include EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry.

How does Novacyt compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

22.6% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 39.7% of EKF Diagnostics shares are owned by company insiders. Comparatively, 0.5% of Novacyt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

EKF Diagnostics has a net margin of 4.12% compared to Novacyt's net margin of -135.96%. EKF Diagnostics' return on equity of 3.01% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Novacyt -135.96%-121.30%-27.98%

EKF Diagnostics currently has a consensus price target of GBX 35, suggesting a potential upside of 32.58%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe EKF Diagnostics is more favorable than Novacyt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Novacyt
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EKF Diagnostics has a beta of 0.526, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Novacyt has a beta of 0.973, suggesting that its share price is 3% less volatile than the broader market.

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.20£4.68M£0.4756.17
Novacyt£20.03M1.50-£36.80M-£43.00N/A

In the previous week, EKF Diagnostics and EKF Diagnostics both had 1 articles in the media. EKF Diagnostics' average media sentiment score of 0.00 beat Novacyt's score of -0.49 indicating that EKF Diagnostics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EKF Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Novacyt
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

EKF Diagnostics beats Novacyt on 14 of the 15 factors compared between the two stocks.

How does Novacyt compare to Creo Medical Group?

Novacyt (LON:NCYT) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Novacyt had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Creo Medical Group. Creo Medical Group's average media sentiment score of 0.05 beat Novacyt's score of -0.49 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
Novacyt Neutral
Creo Medical Group Neutral

Novacyt has a beta of 0.973, indicating that its share price is 3% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6238419, indicating that its share price is 62% more volatile than the broader market.

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 45.2% of Creo Medical Group shares are owned by institutional investors. 0.5% of Novacyt shares are owned by insiders. Comparatively, 4.1% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Creo Medical Group has lower revenue, but higher earnings than Novacyt. Creo Medical Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.50-£36.80M-£43.00N/A
Creo Medical Group£6M9.53-£25.04M-£1.00N/A

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -135.96%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-135.96% -121.30% -27.98%
Creo Medical Group 88.33%9.56%-20.09%

Summary

Creo Medical Group beats Novacyt on 10 of the 13 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -135.96%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
Novacyt -135.96%-121.30%-27.98%

75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 12.8% of Intelligent Ultrasound Group shares are owned by company insiders. Comparatively, 0.5% of Novacyt shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Intelligent Ultrasound Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
Novacyt£20.03M1.50-£36.80M-£43.00N/A

In the previous week, Novacyt had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Intelligent Ultrasound Group. Intelligent Ultrasound Group's average media sentiment score of 0.00 beat Novacyt's score of -0.49 indicating that Intelligent Ultrasound Group is being referred to more favorably in the media.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
Novacyt Neutral

Intelligent Ultrasound Group has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Novacyt has a beta of 0.973, meaning that its share price is 3% less volatile than the broader market.

Summary

Intelligent Ultrasound Group beats Novacyt on 8 of the 12 factors compared between the two stocks.

How does Novacyt compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Inspiration Healthcare Group has a net margin of -25.32% compared to Novacyt's net margin of -135.96%. Inspiration Healthcare Group's return on equity of -69.35% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-25.32% -69.35% -3.47%
Novacyt -135.96%-121.30%-27.98%

In the previous week, Inspiration Healthcare Group and Inspiration Healthcare Group both had 1 articles in the media. Inspiration Healthcare Group's average media sentiment score of 0.00 beat Novacyt's score of -0.49 indicating that Inspiration Healthcare Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inspiration Healthcare Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Novacyt
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inspiration Healthcare Group has higher revenue and earnings than Novacyt. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£45.20M0.52-£12.20M-£13.65N/A
Novacyt£20.03M1.50-£36.80M-£43.00N/A

8.2% of Inspiration Healthcare Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 8.4% of Inspiration Healthcare Group shares are held by company insiders. Comparatively, 0.5% of Novacyt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Inspiration Healthcare Group has a beta of 0.717, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Novacyt has a beta of 0.973, meaning that its stock price is 3% less volatile than the broader market.

Summary

Inspiration Healthcare Group beats Novacyt on 8 of the 12 factors compared between the two stocks.

How does Novacyt compare to RUA Life Sciences?

Novacyt (LON:NCYT) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -135.96%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-135.96% -121.30% -27.98%
RUA Life Sciences -3.26%-2.03%-17.50%

In the previous week, Novacyt had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for RUA Life Sciences. RUA Life Sciences' average media sentiment score of 0.00 beat Novacyt's score of -0.49 indicating that RUA Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Novacyt Neutral
RUA Life Sciences Neutral

RUA Life Sciences has lower revenue, but higher earnings than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.50-£36.80M-£43.00N/A
RUA Life Sciences£4.11M2.61-£2.66MN/AN/A

Novacyt has a beta of 0.973, indicating that its share price is 3% less volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.968, indicating that its share price is 3% less volatile than the broader market.

10.7% of Novacyt shares are held by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are held by institutional investors. 0.5% of Novacyt shares are held by company insiders. Comparatively, 7.3% of RUA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

RUA Life Sciences beats Novacyt on 7 of the 12 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCYT vs. The Competition

Export
MetricNovacytMedical Devices IndustryMedical SectorLON Exchange
Market Cap£30.07M£2.07B£6.26B£2.78B
Dividend YieldN/A2.68%2.69%6.13%
P/E Ratio-0.9714.1922.35364.73
Price / Sales1.50120.09555.6087,561.71
Price / Cash0.5815.9942.3127.85
Price / Book0.424.399.827.74
Net Income-£36.80M£144.75M£3.56B£5.88B
7 Day Performance-17.66%1.18%-1.16%6.46%
1 Month Performance56.02%-0.23%3.85%9.67%
1 Year Performance-8.71%5.04%27.33%75.31%

Novacyt Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCYT
Novacyt
N/AGBX 41.50
+3.5%		N/A-16.4%£30.07M£20.03MN/A120
EKF
EKF Diagnostics
1.8648 of 5 stars		GBX 27.40
-0.4%		GBX 35
+27.7%		+3.5%£117.96M£51.56M58.30356
CREO
Creo Medical Group
N/AGBX 14.50
flat		GBX 40
+175.9%		-8.9%£59.81M£6MN/A279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
IHC
Inspiration Healthcare Group
N/AGBX 29.60
+1.3%		N/A+11.3%£26.54M£45.20MN/A224

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NCYT) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel